Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

1.3. Revenue and recurring EBITDA

1.6 Other revenue

1.6 Other revenue

€ million

2020

2019

Actual rates

CER

Contract manufacturing sales

152

109

39%

39%

Partnerships in Japan

6

20

-71%

-71%

Other

41

26

59%

66%

Other revenue

199

155

28%

29%

Other revenue went up to € 200 million or by (+28%).

Contract manufacturing sales increased to € 152 million from € 109 million, as divestitures led to higher activity for contract manufacturing.

Partnering activities in Japan (Otsuka for E Keppra® and Neupro®, Daiichi Sankyo for Vimpat® and Astellas for Cimzia®) reached a total of € 6 million after € 20 million, reflecting the sales milestone received for E Keppra® in 2019. The UCB team took over distribution of E Keppra® from partner Otsuka in October 2020.

Other” revenue reached € 41 million thanks to milestones and other payments from R&D partners and licencing partners, including Biogen for co-development of dapirolizumab pegol and the new partnership with Roche and Genentech for the global development and commercialization of bepranemab.